Search
for
Sort by
Research 30 of 942
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- PCR108 QUALITATIVE AND PSYCHOMETRIC EVALUATION OF THE CLINRO MEASURE FOR EYEBROW HAIR LOSS AND CLINRO MEASURE FOR EYELASH HAIR LOSS IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
- 63532 Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
- Eyelash trichomegaly: Report of a case following diffuse hair loss associated with transient malnutrition
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Eyelashes: Anatomical and Physiological Features, Eyelash Loss and Trichomegaly: Review
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Eyelash alopecia areata: case series and literature review
- Development and validation of the Brigham Eyelash Tool for Alopecia (BELA): A measure of eyelash alopecia areata
- Eyelash Trichomegaly: A Rare Presenting Feature of Systemic Lupus Erythematosus.
- Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
- Dr Shoji Okuda (1886-1962): The great pioneer of punch graft hair transplantation
- Hair transplantation: standard guidelines of care.
- Eyelash Preservation During Chemotherapy and Topical Prostaglandin Therapy
- FUE Hair Transplantation
- A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders
- Special Forms of Hair Transplantation
- Abstract P5-21-05: ERALOP study: Post adjuvant FEC - docetaxel chemotherapy for early breast cancer: Hair regrowth in the real life
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis
- Hair diameter evaluation in different regions of the safe donor area in Asian populations
- Is There a Role for Radiofrequency Devices in Hair?